Single-blind, placebo controlled randomised clinical study of chitosan for body weight reduction

Nutrition Journal

Volumn 15, Issue 1, 2016, Pages

  Trivedi, Vr ^a   Satia, Mc ^a   Deschamps, A ^b   Maquet, V ^b   Shah, Rb ^c   Zinzuwadia, Ph ^d   Trivedi, Jv ^e  

^a Titanium City Centre   (India)

^b KITOZYME SA   (Belgium)

^c Poojan Multispecialty Hospital   (India)

^d DHL Research Centre   (India)

^e SAL Hospital and Medical Institute   (India)

Author keywords

Anthropometric measurements; Body composition; Body weight; Chitosan; HbA1C; Obesity; Randomised

Indexed keywords

CHITOSAN; HEMOGLOBIN A1C; PLACEBO; GLYCOSYLATED HEMOGLOBIN; PYRIDINE DERIVATIVE; V 10367;

ABDOMINAL CIRCUMFERENCE; ADULT; ARTICLE; BODY FAT; BODY MASS; CALORIC INTAKE; CONTROLLED STUDY; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; FEEDING BEHAVIOR; FEMALE; HEMOGLOBIN BLOOD LEVEL; HIP CIRCUMFERENCE; HUMAN; INTRAABDOMINAL FAT; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MUSCLE MASS; OBESITY; PHASE 4 CLINICAL TRIAL; QUALITY OF LIFE ASSESSMENT; RANDOMIZED CONTROLLED TRIAL; SHORT FORM 36; TREATMENT DURATION; WAIST CIRCUMFERENCE; WAIST HIP RATIO; WEIGHT REDUCTION; ADOLESCENT; AGED; BIOASSAY; BODY COMPOSITION; DIETARY SUPPLEMENT; DOSE RESPONSE; LIFESTYLE; METABOLISM; MIDDLE AGED; OVERWEIGHT; QUALITY OF LIFE; SINGLE BLIND PROCEDURE; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; BODY COMPOSITION; BODY MASS INDEX; CHITOSAN; DIETARY SUPPLEMENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDPOINT DETERMINATION; ENERGY INTAKE; FEEDING BEHAVIOR; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; LIFE STYLE; MALE; MIDDLE AGED; OBESITY; OVERWEIGHT; PYRIDINES; QUALITY OF LIFE; SINGLE-BLIND METHOD; WEIGHT LOSS; YOUNG ADULT;

EID: 84954111119     PISSN: None     EISSN: 14752891     Source Type: Journal    
DOI: 10.1186/s12937-016-0122-8     Document Type: Article

References (48)

1. Sengupta K, Mishra AT, Rao MK, Sarma KV, Krishnaraju AV, Trimurtulu G. Efficacy and tolerability of a novel herbal formulation for weight management in obese subjects: a randomized double blind placebo controlled clinical study. Lipids Health Dis. 2012;11(122):11-122
2. Nammi S, Koka S, Chinnala KM, Boini KM. Obesity: an overview on its current perspectives and treatment options. Nutr J. 2004;3:3
3. Taylor RW, Keil D, Gold EJ, Williams SM, Goulding A. Body mass index, waist girth, and waist-to-hip ratio as indexes of total and regional adiposity in women: evaluation using receiver operating characteristic curves. Am J Clin Nutr. 1998;67(1):44-9
4. About Obesity [ http://www.worldobesity.org/site-media/uploads/IASO-Advocacy-toolkit-Oct13.pdf ]
5. Daniels S. Pharmacological treatment of obesity in paediatric patients. Paediatr Drugs. 2001;3(6):405-10
6. Daniels SR, Arnett DK, Eckel RH, Gidding SS, Hayman LL, Kumanyika S, et al. Overweight in children and adolescents: pathophysiology, consequences, prevention, and treatment. Circulation. 2005;111(15):1999-2012
7. Brenot F, Herve P, Petitpretz P, Parent F, Duroux P, Simonneau G. Primary pulmonary hypertension and fenfluramine use. Br Heart J. 1993;70(6):537-41
8. Rizzo M, Perez-Martinez P, Nikolic D, Montalto G, Lopez-Miranda J. Emerging approaches for the treatment of hypertriglyceridemia. Expert Opin Pharmacother. 2013;14(14):1869-73
9. Astrup A. Dietary composition, substrate balances and body fat in subjects with a predisposition to obesity. Int J Obes Relat Metab Disord. 1993;17(3):S41-2
10. Schiller RN, Barrager E, Schauss AG, Nichols EJ. A randomized, double-blind, placebo-controlled study examining the effects of a rapidly soluble Chitosan dietary supplement on weight loss and body composition in overweight and mildly obese individuals. J Am Nutraceut Assoc. 2001;4:42-9
11. Mesa Ospina N, Ospina Alvarez SP, Escobar Sierra DM, Rojas Vahos DF, Zapata Ocampo PA, Ossa Orozco CP CP. Isolation of chitosan from Ganoderma lucidum mushroom for biomedical applications. J Mater Sci Mater Med. 2015;26(3):135. doi: 110.1007/s10856-10015-15461-z. Epub 12015 Feb 10826
12. Pittler MH, Abbot NC, Harkness EF, Ernst E. Randomized, double-blind trial of chitosan for body weight reduction. Eur J Clin Nutr. 1999;53(5):379-81
13. Muzzarelli RAA. Chitin. Oxford, England: Pergamon Press; 1977
14. Mhurchu CN, Poppitt SD, McGill AT, Leahy FE, Bennett DA, Lin RB, et al. The effect of the dietary supplement, Chitosan, on body weight: a randomised controlled trial in 250 overweight and obese adults. Int J Obes Relat Metab Disord. 2004;28(9):1149-56
15. Sugano M, Fujikawa T, Hiratsuji Y, Nakashima K, Fukuda N, Hasegawa Y. A novel use of chitosan as a hypocholesterolemic agent in rats. Am J Clin Nutr. 1980;33(4):787-93
16. Nauss JL, Thompson JL, Nagyvary J. The binding of micellar lipids to chitosan. Lipids. 1983;18(10):714-9
17. Ebihara K, Schneeman BO. Interaction of bile acids, phospholipids, cholesterol and triglyceride with dietary fibers in the small intestine of rats. J Nutr. 1989;119(8):1100-6
18. Kanauchi O, Deuchi K, Imasato Y, Kobayashi E. Increasing Effect of a Chitosan and Ascorbic Acid Mixture on Fecal Dietary Fat Excretion. Biosci Biotechnol Biochem. 1994;58(9):1617-20
19. Maezaki Y, Tsuji K, Nakagawa Y, Kawai Y, Akimoto M, Tsugita T, et al. Hypocholesterolemic Effect of Chitosan in Adult Males. Biosci Biotechnol Biochem. 1993;57(9):1439-44
20. Sciutto AM, Colombo P. Lipid-lowering effect of chitosan dietary integrator and hypocaloric diet in obese subjects. Acta Toxicol Ther. 1995;16(4):215-30
21. Giustina A, Ventura P. Weight-reducing regimens in obese subjects: effects of a new dietary fiber integrator. Acta Toxicol Ther. 1995;16(4):199-214
22. Ventura P. Lipid lowering activity of chitosan, a new dietary integrator. Chitin Enzymology. 1996;2:55-62
23. Kaats GR, Michalek JE, Preuss HG. Evaluating efficacy of a chitosan product using a double-blinded, placebo-controlled protocol. J Am Coll Nutr. 2006;25(5):389-94
24. Ho SC, Tai ES, Eng PH, Tan CE, Fok AC. In the absence of dietary surveillance, chitosan does not reduce plasma lipids or obesity in hypercholesterolaemic obese Asian subjects. Singapore Med J. 2001;42(1):6-10
25. Pokhis K, Bitterlich N, Cornelli U, Cassano G. Efficacy of polyglucosamine for weight loss-confirmed in a randomized double-blind, placebo-controlled clinical investigation. BMC Obes. 2015;2(25):015-0053
26. Abelin J, Lassus A. L-112 Biopolymer - Fat binder as a weight reducer in patients with moderate obesity. Helsinki: Medical research report performed at ARS Medicina; 1994
27. Ware JE, Kosinski M, Kellar SD. SF-36 physical and mental health summary scales: a users manual. 2nd ed. Boston, MA: The Health Institute, New England Medical Centre; 1994
28. Jenkinson C, Coulter A, Wright L. Short form 36 (SF36) health survey questionnaire: normative data for adults of working age. BMJ. 1993;306(6890):1437-40
29. Veneroni G, Veneroni F, Contos S, Tripodi S, De Bernardi M, Guarino C, et al. Effect of a new chitosan dietary integrator and hypocaloric diet on hyperlipidemia and overweight in obese patients. Acta Toxicologica et Therapeutica. 1996;17:53-70
30. Wadstein J, Thom E, Heldman E, Gudmunsson S, Lilja B: Biopolymer L112, a chitosan with fat binding properties and potential as a weight reducing agent: a review of in vitro and in vivo experiments. In: Chitosan per os - from dietary supplement to drug carrier. Edited by A.A.Muzzarelli R: Atec Edizioni, Grottammare; 2000: 65-76
31. Cornelli U, Belcaro G, Cesarone MR, Cornelli M. Use of polyglucosamine and physical activity to reduce body weight and dyslipidemia in moderately overweight subjects. Minerva Cardioangiol. 2008;56(5 Suppl):71-8
32. American College of Cardiology/American Heart Association Task Force on Practice Guidelines, Obesity Expert Panel. Expert panel report: Guidelines (2013) for the management of overweight and obesity in adults. Obesity. 2014;22(S2):S41-S410
33. Kopelman PG. The effects of weight loss treatments on upper and lower body fat. Int J Obes Relat Metab Disord. 1997;21(8):619-25
34. Bray GA, Greenway FL, Molitch ME, Dahms WT, Atkinson RL, Hamilton K. Use of anthropometric measures to assess weight loss. Am J Clin Nutr. 1978;31(5):769-73
35. Sjostrom L, Narbro K, Sjostrom D. Costs and benefits when treating obesity. Int J Obes Relat Metab Disord. 1995;19(6):S9-S12
36. Kerch G. The Potential of Chitosan and Its Derivatives in Prevention and Treatment of Age-Related Diseases. Mar Drugs. 2015;13(4):2158
37. Patti AM, Katsiki N, Nikolic D, Al-Rasadi K, Rizzo M. Nutraceuticals in Lipid-Lowering Treatment: A Narrative Review on the Role of Chitosan. Angiology. 2015;66(5):416-21
38. Caan B, Armstrong MA, Selby JV, Sadler M, Folsom AR, Jacobs D, et al. Changes in measurements of body fat distribution accompanying weight change. Int J Obes Relat Metab Disord. 1994;18(6):397-404
39. Deibert P, Konig D, Vitolins MZ, Landmann U, Frey I, Zahradnik HP, et al. Effect of a weight loss intervention on anthropometric measures and metabolic risk factors in pre- versus postmenopausal women. Nutr J. 2007;6:31
40. Garcia-Rios A, Nikolic D, Perez-Martinez P, Lopez-Miranda J, Rizzo M, Hoogeveen RC. LDL and HDL subfractions, dysfunctional HDL: treatment options. Curr Pharm Des. 2014;20(40):6249-55
41. Halloran LG, Schwartz CC, Vlahcevic ZR, Nisman RM, Swell L. Evidence for high-density lipoprotein-free cholesterol as the primary precursor for bile-acid synthesis in man. Surgery. 1978;84(1):1-7
42. Rizzo M, Giglio RV, Nikolic D, Patti AM, Campanella C, Cocchi M, et al. Effects of chitosan on plasma lipids and lipoproteins: a 4-month prospective pilot study. Angiology. 2014;65(6):538-42. doi: 510.1177/0003319713493126. Epub 0003319713492013 Jun 0003319713493118
43. O'Rahilly S. Science, medicine, and the future. Non-insulin dependent diabetes mellitus: the gathering storm. BMJ. 1997;314(7085):955-9
44. Jo SH, Ha KS, Moon KS, Kim JG, Oh CG, Kim YC, et al. Molecular Weight Dependent Glucose Lowering Effect of Low Molecular Weight Chitosan Oligosaccharide (GO2KA1) on Postprandial Blood Glucose Level in SD Rats Model. Int J Mol Sci. 2013;14(7):14214-24
45. Kim HJ, Ahn HY, Kwak JH, Shin DY, Kwon YI, Oh CG, et al. The effects of chitosan oligosaccharide (GO2KA1) supplementation on glucose control in subjects with prediabetes. Food Funct. 2014;5(10):2662-9. doi: 2610.1039/c2664fo00469h. Epub 02014 Sep 00415
46. Ni Mhurchu C, Bennett D, Lin R, Hackett M, Jull A, Rodgers A. Obesity and health-related quality of life: results from a weight loss trial. N Z Med J. 2004;117(1207):U1211
47. Onyike CU, Crum RM, Lee HB, Lyketsos CG, Eaton WW. Is obesity associated with major depression? Results from the Third National Health and Nutrition Examination Survey. Am J Epidemiol. 2003;158(12):1139-47
48. Kaukua JK, Pekkarinen TA, Rissanen AM. Health-related quality of life in a randomised placebo-controlled trial of sibutramine in obese patients with type II diabetes. Int J Obes Relat Metab Disord. 2004;28(4):600-5